首页> 外文期刊>Endocrinology, Diabetes & Metabolism >Short‐and long‐term administration of imeglimin counters cardiorenal dysfunction in a rat model of metabolic syndrome
【24h】

Short‐and long‐term administration of imeglimin counters cardiorenal dysfunction in a rat model of metabolic syndrome

机译:代谢综合征大鼠模型中IMEGLIMIN计数器心肺功能障碍的短期和长期施用

获取原文
           

摘要

Introduction Imeglimin, a glucose‐lowering agent targeting mitochondrial bioenergetics, decreases reactive oxygen species (ROS) overproduction and improves glucose homeostasis. We investigated whether this is associated with protective effects on metabolic syndrome‐related left ventricular (LV) and vascular dysfunctions. Methods We used Zucker fa/fa rats to assess the effects on LV function, LV tissue perfusion, LV oxidative stress and vascular function induced by imeglimin administered orally for 9 or 90?days at a dose of 150?mg/kg twice daily. Results Compared to untreated animals, 9‐ and 90‐day imeglimin treatment decreased LV end‐diastolic pressure and LV end‐diastolic pressure‐volume relation, increased LV tissue perfusion and decreased LV ROS production. Simultaneously, imeglimin restored acetylcholine‐mediated coronary relaxation and mesenteric flow‐mediated dilation. One hour after imeglimin administration, when glucose plasma levels were not yet modified, imeglimin reduced LV mitochondrial ROS production and improved LV function. Ninety‐day imeglimin treatment reduced related LV and kidney fibrosis and improved kidney function. Conclusion In a rat model, mimicking Human metabolic syndrome, imeglimin immediately countered metabolic syndrome‐related cardiac diastolic and vascular dysfunction by reducing oxidative stress/increased NO bioavailability and improving myocardial perfusion and after 90‐day treatment myocardial and kidney structure, effects that are, at least in part, independent from glucose control.
机译:引言IMEGLIMIN,一种靶向线粒体生物能器学的葡萄糖降低剂,降低了活性氧(ROS)过量生产并改善了葡萄糖稳态。我们调查了这是否与对代谢综合征相关的左心室(LV)和血管功能障碍的保护作用有关。方法采用Zucker Fa / FA大鼠评估对LV功能,LV组织灌注,LV氧化应激和由IMEGLIMIN诱导的LV氧化应激和血管功能的影响,每天两次以150×mg / kg的剂量给药。结果与未处理的动物相比,9-〜90天的IMEGLIMIN处理降低了LV端舒张压和LV端舒张压体积关系,增加了LV组织灌注和降低的LV ROS生产。同时,Imeglimin恢复乙酰胆碱介导的冠状动脉弛豫和肠系膜流动介导的扩张。 IMEGLIMIN给药后一小时,当葡萄糖血浆水平尚未改性时,IMEGLIMIN降低了LV线粒体ROS产生和改善的LV功能。 90天的IMEGLIMIN治疗减少了相关的LV和肾纤维化和改善的肾功能。结论在大鼠模型中,模拟人类代谢综合征,IMEGLIMIN立即通过降低氧化胁迫/增加生物利用度和改善心肌灌注和90天治疗心肌和肾结构,效果的氧化综合征相关的心脏舒张和血管功能障碍立即反驳代谢综合征相关的心脏舒张和血管功能障碍。至少部分地,独立于葡萄糖控制。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号